证券代码：600267 证券简称：海正药业 公告编号：临 2025-26 号 浙江海正药业股份有限公司 关于公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"或"海正药业"）收 到国家药品监督管理局（以下简称"国家药监局"）核准签发的丁二磺酸腺苷蛋 氨酸肠溶片《药品补充申请批准通知书》，公司药品丁二磺酸腺苷蛋氨酸肠溶片 已通过仿制药质量和疗效一致性评价。现就相关情况公告如下： 一、药品的基本情况 药品名称：丁二磺酸腺苷蛋氨酸肠溶片 剂型：片剂 注册分类：化学药品 上市许可持有人：浙江海正药业股份有限公司 生产企业：浙江海正药业股份有限公司 受理号：CYHB2450105 通知书编号：2025B01724 原药品批准文号：国药准字 H20133197 申请内容：仿制药质量和疗效一致性评价 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医 疗器械审评审批制度的意见》(国发〔2015〕44 号)和《关于仿制药质量和疗效 一致性评价工作 ...

Core Viewpoint - The company has successfully passed the consistency evaluation of the quality and efficacy of its generic drug, Adenosine Methionine Disulfate Enteric-Coated Tablets, which is indicated for cholestasis due to liver cirrhosis [1] Group 1: Product Information - The drug is suitable for pre-cirrhosis and cholestasis caused by liver cirrhosis [1] - The original product was developed by Abbott Laboratories [1] Group 2: Market Potential - The global sales forecast for the drug in 2024 is approximately $170 million, with domestic sales expected to be around $38.4 million [1] - The company's projected sales for 2024 are about 145 million RMB [1]

Core Insights - As of April 21, 2024, 2,246 companies have released their annual reports, with 1,197 reporting a year-on-year increase in net profit, while 1,049 reported a decline [1] - A total of 1,341 companies saw an increase in operating revenue, whereas 904 experienced a decrease [1] - Companies that reported simultaneous growth in both net profit and operating revenue include 940 firms, while 648 companies saw declines in both metrics [1] - Notably, 234 companies achieved a net profit growth rate exceeding 100%, with Zhengdan Co., Ltd. leading at an impressive 11,949.39% increase [1] Company Performance Summary - Zhengdan Co., Ltd. (300641) reported earnings per share of 2.35 yuan, with a net profit of 1,189.89 million yuan, reflecting a year-on-year increase of 11,949.39%, and operating revenue of 348.02 million yuan, up 126.31% [1] - Guangxi Energy (600310) reported earnings per share of 0.043 yuan, with a net profit of 62.99 million yuan, a significant increase of 3,704.04%, but a decline in operating revenue by 76.48% to 393.16 million yuan [1] - Siwei (688213) achieved earnings per share of 0.98 yuan, with a net profit of 39.27 million yuan, marking a 2,662.76% increase, and operating revenue of 596.81 million yuan, up 108.87% [1] - Other notable performers include Andis (600299) with a net profit of 120.43 million yuan (up 2,208.66%) and operating revenue of 1,553.43 million yuan (up 17.83%) [1] - Companies like Huabei Pharmaceutical (600812) and Jiangsu Suo (600746) also reported significant changes in their financial metrics, with varying trends in net profit and operating revenue [1][2]

Core Viewpoint - The company is actively engaging with investors to discuss its strategic direction, focusing on research and development in innovative drugs, generic drugs, raw materials, and medical aesthetics, while also emphasizing the importance of synthetic biology in its growth strategy [1][2]. Group 1: R&D Strategy - The company has established a systematic and efficient R&D project initiation mechanism, focusing on three core areas: innovative drugs, generic drugs, and raw materials, along with medical aesthetics [1]. - The R&D strategy is driven by the dual focus on clinical and market value, aiming to create a well-structured R&D pipeline that emphasizes differentiated advantages and market competitiveness [2]. - The Shanghai Innovation Drug R&D Center is a key strategic asset, focusing on cutting-edge technologies such as small nucleic acids and AI-assisted R&D, with completion expected this year [3]. Group 2: Financial Performance and Projections - The company anticipates a reduction in unit product depreciation costs as production capacity utilization increases, following a peak in depreciation last year [4]. - A 50% provision for bad debts has been made for accounts receivable from Puli Pharmaceutical due to its ongoing delisting process and potential litigation risks [5]. Group 3: Product and Market Development - The company’s product "Tezhixing" is fully utilized with a commercial inventory cycle of about three days, indicating strong demand, and an expansion project is expected to be operational by mid-next year [5]. - The CSO product line, particularly "Niuzaili" and "Jierun," is expected to see significant growth due to demographic trends and improved accessibility through distribution adjustments [5]. Group 4: Animal Health Business - The company has a 31-year history in the animal health sector, with a shift towards pet medications expected to account for over 50% of sales by 2025, positioning it as a leading brand in the domestic pet medicine market [6]. - The company is focused on solidifying performance in its animal health segment, with plans for potential future public offerings subject to regulatory compliance [6]. Group 5: International Expansion - The company views the global market as an opportunity, with a strategy to integrate international operations across regions such as Brazil, the Middle East, and Eastern Europe, while also preparing for markets in Japan and Southeast Asia [7]. - The international business strategy includes not only exports but also establishing overseas manufacturing and leveraging e-commerce [7]. Group 6: Synthetic Biology and Differentiation - The company’s approach to synthetic biology is based on leveraging existing industrial capabilities, with product launches expected as early as the second half of this year [8]. - The company aims to differentiate itself from leading innovative drug firms by focusing on solidifying its industrial foundation and pursuing a unique strategy in synthetic biology and high-end manufacturing [8][9].

证券代码：600267 证券简称：海正药业 公告编号：临 2025-25 号 浙江海正药业股份有限公司 关于投资者接待日活动举办情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司始终坚守"临床价值与市场价值双轮驱动"的核心理念，精心规划研发 战略版图：以人用药研发为核心，医美大健康和动物保健作为两大重要发展翼， 全力塑造"大海正制药集团"的卓越品牌形象。通过精准锚定研发方向，以高效 的推进策略，打造出结构合理、层次分明的研发管线体系。这一体系将以上市拳 头产品为核心，兼具差异化优势、创新特质与市场竞争力，形成可持续发展的良 性循环。 此外，结合合成生物学广阔的市场前景，以及公司自身的战略发展规划，公 司正积极布局该领域。依托在生物制造领域深厚的产业技术转化能力与强大的产 能优势，公司将通过自主创新研发与外部资源合作双轨并行的模式，加快推动一 批产业化项目落地，抢占行业发展先机。 问题二：请介绍下上海研发中心的建设情况？ 浙江海正药业股份有限公司（以下简称"公司"）投资者接待日活动于2025 年4月18日（星期五） ...

证券代码：600267 证券简称：海正药业 公告编号：临 2025-19 号 浙江海正药业股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 4 月 18 日 | 1、出席会议的股东和代理人人数 | 225 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 476,618,428 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 40.7829 | 注：截止本次股东大会股权登记日，公司总股本为 1,198,848,196 股，其中公司回购专用账 户的股份数量为 30,176,300 股，该等回购的股份不享有表决权，故本次股东大会享有表决权 的股份总数为 1,168,671,896 股。 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 (二)股东大会召开的地点：浙江海正 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司董事会 浙江海正药业股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开 的第十届董事会第一次会议，以 9 票同意，0 票反对，0 票弃权的表决结果审议 通过了《关于选举公司第十届董事会董事长的议案》《关于聘任公司总裁的议案》， 为保证公司董事会的正常运转，依法开展工作，根据《公司章程》《总裁工作细 则》的有关规定，董事会同意选举肖卫红先生为公司董事长，同意聘任肖卫红先 生为公司总裁，主持公司的生产经营管理等工作，任期至本届董事会届满时止。 肖卫红先生简历如下： 二○二五年四月十九日 肖卫红：男，1968 年 9 月出生，本科，中国农工民主党上海市浦东新区副主 委，政协上海市浦东新区常委，中国香料香精化妆品工业协会特邀副理事长，中 国药师协会副会长，中国民族卫生协会常务理事，浙江省药学会副会长，浦东国 际商会副会长，上海中青年知识分子联谊会会员，北京大学国家发展研究院 MBA 职业导师。历任辉瑞制药中国有限公司人力资源部总监、商务及多元化 ...

政策动向 4月16日，东方生物公告称，公司近日取得新冠/甲乙流/合胞病毒/腺病毒抗原联合检测试剂（胶体金 法）的境外医疗器械注册证，该产品用于定性检测鼻拭子中新冠病毒、甲型流感、乙型流感、合胞病毒 和腺病毒标本，旨在帮助快速鉴别诊断呼吸系统新冠病毒、甲乙型流感、合胞病毒或腺病毒的感染。该 产品取得欧盟CE认证，有利于整体市场拓展，但实际销售业绩取决于产品竞争力和市场销售能力，目 前尚无法预测对公司未来经营业绩的影响。 国家发展改革委价格成本和认证中心组织召开医药产业相关政策座谈会 4月16日，据国家发展和改革委价格成本和认证中心官网，4月9日，价格成本和认证中心组织召开医药 产业相关政策座谈会。会议由中心副主任初绽同志主持，来自生物医药企业的代表和行业研究机构的专 家围绕促进医药产业高质量发展进行座谈交流，并提出了完善产业相关政策的意见和建议。我委相关司 局同志和中心民生价格成本处全体同志参加会议。 国台办：积极鼓励和支持两岸医药卫生交流 4月16日，国务院台办举行例行新闻发布会。发言人朱凤莲表示，近年来，大陆医疗事业快速发展，医 疗水平不断提高，为台湾同胞来大陆生活、就医提供了更好保障。我们将继续秉持"两岸 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600267 证券简称：海正药业 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 ■ (二)非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 二、股东信息 (一)普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息 ...

海正药业（600267）公告，2025年第一季度营收为26.32亿元，同比下降3.48%；净利润为1.94亿元，同 比下降21.85%。 ...